10.95
price down icon6.81%   -0.80
after-market After Hours: 11.00 0.05 +0.46%
loading
Zymeworks Inc. stock is traded at $10.95, with a volume of 1.16M. It is down -6.81% in the last 24 hours and down -14.12% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$11.75
Open:
$11.4
24h Volume:
1.16M
Relative Volume:
2.21
Market Cap:
$761.87M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-7.2517
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
-11.48%
1M Performance:
-14.12%
6M Performance:
-12.89%
1Y Performance:
+13.35%
1-Day Range:
Value
$10.61
$11.75
1-Week Range:
Value
$10.61
$12.10
52-Week Range:
Value
$7.97
$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name
Name
Zymeworks Inc.
Name
Phone
604-678-1388
Name
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
Employee
170
Name
Twitter
@ZymeworksInc
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ZYME's Discussions on Twitter

Compare ZYME with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZYME
Zymeworks Inc.
10.95 761.87M 62.71M -112.51M -96.01M -1.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-16-24 Upgrade JP Morgan Neutral → Overweight
Nov-07-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-01-24 Downgrade Wells Fargo Overweight → Equal Weight
Mar-21-23 Resumed Wells Fargo Overweight
Jan-04-23 Reiterated H.C. Wainwright Neutral
Dec-20-22 Upgrade Jefferies Hold → Buy
Nov-01-22 Downgrade H.C. Wainwright Buy → Neutral
Oct-21-22 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-04-22 Resumed Wells Fargo Overweight
May-05-22 Upgrade Guggenheim Neutral → Buy
Mar-15-22 Initiated Evercore ISI Outperform
Dec-10-21 Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21 Resumed Guggenheim Neutral
Oct-07-21 Initiated Jefferies Hold
Mar-31-21 Initiated Credit Suisse Outperform
Feb-25-21 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-08-21 Resumed H.C. Wainwright Buy
Jan-25-21 Downgrade Citigroup Buy → Neutral
Sep-29-20 Resumed JP Morgan Neutral
Aug-06-20 Initiated SVB Leerink Outperform
Jan-10-20 Initiated Wolfe Research Outperform
Dec-09-19 Initiated JP Morgan Neutral
Nov-25-19 Initiated H.C. Wainwright Buy
Nov-20-19 Initiated Guggenheim Buy
Sep-30-19 Upgrade Raymond James Outperform → Strong Buy
Aug-30-19 Initiated Stifel Buy
Jul-18-19 Initiated Deutsche Bank Buy
May-11-18 Upgrade Barclays Underweight → Equal Weight
Mar-19-18 Initiated Raymond James Outperform
View All

Zymeworks Inc. Stock (ZYME) Latest News

pulisher
Apr 02, 2025

Zymeworks Inc. sees insider purchases totaling $1.5 million By Investing.com - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Zymeworks Inc. sees insider purchases totaling $1.5 million - Investing.com India

Apr 02, 2025
pulisher
Mar 28, 2025

Ecor1 Capital, Llc Purchases 22,689 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat

Mar 28, 2025
pulisher
Mar 27, 2025

Major Investment Alert: Ecor1 Capital Buys Big in Zymeworks! - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Ecor1 Capital’s Oleg Nodelman buys $1.23 million in Zymeworks stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 26, 2025

Zymeworks to Engage Investors at Upcoming Conferences - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Clinical-Stage Biotech Zymeworks Reveals New Pipeline Insights at Two Major Healthcare Conferences - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Zymeworks to Present Promising Cancer Therapy Data at AACR Meeting - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Zymeworks to Present Preclinical Data on T cell Engager and - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Game-Changing Cancer Drug Results: Zymeworks Reveals 6 Promising Treatments at AACR - Stock Titan

Mar 25, 2025
pulisher
Mar 25, 2025

Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March - Insider Monkey

Mar 25, 2025
pulisher
Mar 24, 2025

EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus

Mar 24, 2025
pulisher
Mar 24, 2025

Zymeworks Inc. sees $1.64 million stock purchase by EcoR1 Capital - Investing.com Philippines

Mar 24, 2025
pulisher
Mar 21, 2025

EcoR1 Capital, LLC's Strategic Acquisition of Zymeworks Inc Shar - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey

Mar 20, 2025
pulisher
Mar 19, 2025

Zymeworks sees over $2.8 million in stock purchases by EcoR1 Capital - Investing.com Australia

Mar 19, 2025
pulisher
Mar 16, 2025

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from Brokerages - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

EcoR1 capital acquires $13.1 million in Zymeworks stock By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

EcoR1 capital acquires $13.1 million in Zymeworks stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Equities Analysts Issue Forecasts for Zymeworks Q1 Earnings - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock? - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Zymeworks (NYSE:ZYME) Now Covered by Analysts at Lifesci Capital - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

LifeSci Capital Initiates Coverage of Zymeworks (ZYME) with Outperform Recommendation - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 13% - Simply Wall St

Mar 11, 2025
pulisher
Mar 11, 2025

Zymeworks (NYSE:ZYME) Price Target Raised to $13.00 at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings) - Benzinga

Mar 10, 2025
pulisher
Mar 10, 2025

Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates - Yahoo Finance

Mar 10, 2025
pulisher
Mar 09, 2025

Citigroup Boosts Zymeworks (NYSE:ZYME) Price Target to $19.00 - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 - Benzinga India

Mar 06, 2025
pulisher
Mar 06, 2025

Zymeworks Inc. (NYSE:ZYME) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 06, 2025
pulisher
Mar 06, 2025

Zymeworks Inc (ZYME) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Zymeworks Inc (ZYME) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights By GuruFocus - Investing.com Canada

Mar 06, 2025
pulisher
Mar 05, 2025

Zymeworks Reports 2024 Financial Results and Pipeline Progress - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks Achieves FDA Approval for Ziihera® - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 05, 2025
pulisher
Mar 05, 2025

Earnings call transcript: Zymeworks Q4 2024 sees modest revenue, stock dips - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks Q4 Net Loss Widens, Revenue Increases; Shares Fall After Hours -March 05, 2025 at 04:55 pm EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks Inc Q4 2024 Earnings: EPS of -$0.31 and Revenue of $31 - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks shares fall as Q4 earnings miss expectations By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks shares fall as Q4 earnings miss expectations - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

How Will Zymeworks' FDA Win for Ziihera Impact Its $122M Annual Loss? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Rhumbline Advisers Buys 15,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance

Mar 04, 2025

Zymeworks Inc. Stock (ZYME) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):